NUVALENT INC's ticker is and the CUSIP is 670703107. A total of 56 filers reported holding NUVALENT INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $286,448,573 | +11.8% | 3,776,016 | +10.7% | 0.01% | +20.0% |
| Q1 2024 | $256,212,487 | +4.2% | 3,412,072 | +2.2% | 0.01% | 0.0% |
| Q4 2023 | $245,779,562 | +150.5% | 3,339,850 | +56.5% | 0.01% | +150.0% |
| Q3 2023 | $98,108,346 | +9.8% | 2,134,182 | +0.7% | 0.00% | 0.0% |
| Q2 2023 | $89,335,458 | +65.4% | 2,118,460 | +2.3% | 0.00% | +100.0% |
| Q1 2023 | $54,012,718 | -9.9% | 2,070,246 | +2.9% | 0.00% | -50.0% |
| Q4 2022 | $59,926,531 | +114.0% | 2,012,308 | +39.7% | 0.00% | +100.0% |
| Q3 2022 | $28,007,000 | +63.9% | 1,440,693 | +14.3% | 0.00% | – |
| Q2 2022 | $17,088,000 | -24.9% | 1,260,165 | -23.0% | 0.00% | -100.0% |
| Q1 2022 | $22,745,000 | +57.3% | 1,637,507 | +115.6% | 0.00% | – |
| Q4 2021 | $14,464,000 | -14.4% | 759,672 | +1.4% | 0.00% | – |
| Q3 2021 | $16,890,000 | – | 748,980 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 19,991,024 | $843,021,482 | 18.00% |
| Fairmount Funds Management LLC | 2,884,492 | $121,639,028 | 17.15% |
| Bain Capital Life Sciences Investors, LLC | 3,577,267 | $150,853,349 | 15.54% |
| COMMODORE CAPITAL LP | 1,150,000 | $48,495,500 | 5.45% |
| Paradigm Biocapital Advisors LP | 1,120,465 | $47,250,009 | 3.65% |
| Perceptive Advisors | 2,194,821 | $92,555,602 | 2.68% |
| Boxer Capital, LLC | 1,210,192 | $51,034 | 2.37% |
| Ikarian Capital, LLC | 272,752 | $11,501,952 | 1.83% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 115,067 | $4,852,375 | 1.50% |
| HighVista Strategies LLC | 72,298 | $3,048,807 | 1.40% |